Cancer Tx Eye Toxicity; ASCO Targets Preauthorization; Liver Transplant for Seniors

Cancer Tx Eye Toxicity; ASCO Targets Preauthorization; Liver Transplant for Seniors

Neoadjuvant immunotherapy for aggressive breast cancer benefited all patients, regardless of race. (American Association for Cancer Research)

Treatments for genitourinary cancers have a risk of a wide range of ophthalmologic toxicities, most of which are mild and short lived, though some can be severe, disabling, and irreversible. (Cureus)

Reflecting advances in treatment, people with early-stage Hodgkin lymphoma have a greater risk of dying of cardiovascular disease than cancer. (Cancer)

The European Medicines Agency announced conditional approval of teclistamab (Tecvayli) for multiple myeloma in the fourth line and beyond.

Seagen and Astellas announced that a trial of first-line treatment for advanced urothelial cancer with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) met the primary outcome, achieving an objective response rate of 64.5%.

The American Society of Clinical Oncology launched a campaign to urge Congress to pass legislation to reform the prior authorization process to ensure patient access to timely cancer treatment.

A small feasibility study showed that changing the sequence of treatments for breast cancer might safely speed up the treatment process and improve outcomes for women who require mastectomy. (Imperial College London, Lancet Oncology)

Bristol Myers Squibb announced that a trial of adjuvant ipilimumab (Yervoy) and nivolumab (Opdivo) after complete or partial nephrectomy did not meet the primary endpoint of improved disease-free survival in localized renal cell carcinoma.

Older patients with early-stage hepatocellular carcinoma lived significantly longer after a liver transplant compared with ablative therapy. (Journal of the American College of Surgeons)

  • Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Read More